Trio goes in for high tech medicines

The Swedish drug discovery company Beactica announces fragment-based drug discovery research collaboration with GE Healthcare and the University of Uppsala.
Beactica announces a new research collaboration agreement with GE Healthcare and the University of Uppsala. The Swedish specialist drug discovery company Beactica was spun out of the University of Uppsala in 2006, and utilises its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics.

This newly announced collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from the University of Uppsala.

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore surface plasmon resonance instruments and applications for fragmentbased drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica’s discovery pipeline.

Kommentera en artikel
Utvalda artiklar


Sänd till en kollega